Building on strong efficacy results, the companies will expand their collaboration to 25,000 patients to identify safety, tolerability, and drug-specific response signals.OXFORD, UK and PORTLAND, ME – 25 February 2026 – Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced the results of the first phase of their collaboration to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like…
Amsbio offers a comprehensive range of pre-made lentiviral particles for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo.
Lentiviral particles provide long-term, stable expression of genes, making them ideal for stable cell line engineering, CRISPR applications, and therapeutic gene transfer.
Key advantages of Amsbio lentiviral particles include their ease of use, high titer, purity, and safety features. These pre-made lentiviral particles come ready-to-use, eliminating the need for transfection reagents and saving…
The pioneering purpose-built life science facility opens in March 2026
Glasgow, February, 2026
Located within the Glasgow Riverside Innovation District (GRID), the highly anticipated Health Innovation Hub (HiH) has secured Panthera as a new tenant ahead of its official opening next month. The announcement further strengthens the Hub’s growing community of healthcare innovators and highlights its role in supporting collaboration, growth and clinical excellence.
Panthera, which recruits patients and runs clinical trials for pharmaceutical and biotech companies and the seven largest Contract…
LONDON, UK and COPENHAGEN, Denmark – February 24, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led the search for Hans T. Schambye, MD, PhD for his appointment to the Board of Directors at BOOST Pharma (“BOOST”), and is now pleased to announce his transition to Chief Executive Officer (CEO). BOOST Pharma is a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead…
22,000 sq ft of space in Wilton Centre’s Technical Development Area (TDA) has been leased to growing companies breathing new life into used metals and accelerating Teesside’s net zero ambitions.
An iconic research space in Europe’s R&D landscape, Wilton Centre near Redcar is home to 60 businesses, with 12 of these operating in its TDA – a 100,000 sq ft complex of four specialised, industrial buildings that can accommodate chemical pilot plants, development rigs, machine testing and light industrial activity.
Recently moving into the TDA is DEScycle, a deep tech company building the next…
In pharma, the question isn’t whether AI can be used — it’s how to use it responsibly, without putting regulatory submissions, scientific credibility, or patient safety at risk.
In our latest white paper, we look at how pharma library and medical information teams are building trust in AI, including:
- Understanding when outputs can be trusted and when human review is non-negotiable
- Knowing what makes AI outputs defensible under regulatory and scientific review
- Defining guardrails before adoptions scales
👉 Download the white paper to see how teams are approaching AI responsibly: https://…
Welcome to the First Edition of Our People Pathways Newsletter for 2026!
As 2026 gathers momentum, we remain focused on building skills, strengthening leadership, and smarter development across the life sciences sector. In this edition you’ll find details of upcoming training courses and new seminars, as well as collaborative events exploring non-clinical strategy and regulatory preparation, and leadership development opportunities. We’re also highlighting our upcoming HR SIG session on the Employment Rights Bill, designed to help HR professionals prepare for significant changes in the…
Sandwich, UK - 18 February 2026: Discovery Park and University of Kent will host their third joint Innovation Showcase on Thursday, 5th March, bringing together academics, industry, clinical partners and funders.
The showcase explores the progress and impact of research projects funded through the Kent UKRI Impact Acceleration Accounts (IAAs), a strategic investment programme designed to accelerate the real-world impact of research.
This event aims to shape future innovation projects and provides opportunities for academics and stakeholders to give feedback on IAAs. Along with presentations…
New Collaboration Brings GOLD Protein–Ligand Docking Capabilities to Sapio ELaiN — the World’s First 3rd‑Generation AI Laboratory Notebook
The Cambridge Crystallographic Data Centre (CCDC), a global leader in structural chemistry data, software, and services, today announced a new strategic technology partnership with Sapio Sciences.
Through this collaboration, the CCDC’s industry‑leading molecular docking software, GOLD, will be integrated into Sapio ELaiN, the world’s first 3rd-generation Electronic Lab Notebook (ELN) and the first true AI Laboratory Notebook (AILN).
This partnership…
Nuclera and leadxpro Partner to Accelerate Structure-based Drug Design for Complex Membrane Proteins
Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets
To de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design
Cambridge, UK, Boston MA, USA and Villigen, Switzerland, 17 February 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery’s™ rapid multiplex membrane protein…